

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Li et al.

Docket No.: PF132P3D2

Application No.: 10/646,770

Confirmation No.: 1254

Filed: August 25, 2003

Art Unit: 1646

For: Antibodies to MCP-4

Examiner: P. M. Mertz

**INFORMATION DISCLOSURE STATEMENT**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Applicants hereby direct the Examiner's attention to references A to EB listed on the attached Form PTO/SB/08.

Copies of references M-EB were submitted by Applicants or cited by the Examiner in connection with the following U. S. Patent Applications: 09/717,209, filed November 22, 2000 (now U.S. Patent No. 6,673,344); 08/613,822, filed February 23, 1996 (now U.S. Patent No. 6,174,995); 08/458,355, filed June 2, 1995 (now U.S. Patent No. 5,981,230); and 08/462,967, filed June 5, 1995 (now abandoned) , The instant application claims priority under 35 U.S.C. § 120 to each of the above-listed patent applications. Accordingly, pursuant to 37 C.F.R. § 1.98(d), the Examiner is directed to the above-listed files for copies of references M-EB.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as “prior art” against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c), although this Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits, the Patent and Trademark Office will consider the Information Disclosure Statement if it is accompanied by the fee as specified in 37 C.F.R. § 1.17(p). Accordingly, the Patent Office is authorized to charge the required fee, and any other fee deemed necessary, to Human Genome Sciences, Inc., Deposit Account No. 08-3425, as noted on the enclosed fee transmittal.

Dated: July 5, 2006

Respectfully submitted,

/Mark J. Hyman, Reg. No. 46,789/

Mark J. Hyman

Registration No.: 46,789

HUMAN GENOME SCIENCES, INC.

Intellectual Property Dept.

14200 Shady Grove Road

Rockville, Maryland 20850

(240) 314-1224